Abstract
Oral squamous cell carcinoma (OSCC) is amongst the most common cancers worldwide, with more than 377,000 new cases worldwide each year. OSCC prognosis remains poor, related to cancer presentation at a late stage indicating the need for early detection to improve patient prognosis. OSCC is often preceded by a premalignant state known as oral epithelial dysplasia (OED), which is diagnosed and graded using subjective histological criteria leading to variability and prognostic unreliability. In this work, we propose a deep learning approach for the development of prognostic models for malignant transformation and their association with clinical outcomes in histology whole slide images (WSIs) of OED tissue sections. We train a weakly supervised method on OED (n= 137) cases with transformation (n= 50) status and mean malignant transformation time of 6.51 years (±5.35 SD). Performing stratified 5-fold cross-validation achieves an average AUROC of ∼0.78 for predicting malignant transformations in OED. Hotspot analysis reveals various features from nuclei in the epithelium and peri-epithelial tissue to be significant prognostic factors for malignant transformation, including the count of peri-epithelial lymphocytes (PELs) (p < 0.05), epithelial layer nuclei count (NC) (p < 0.05) and basal layer NC (p < 0.05). Progression free survival using the Epithelial layer NC (p < 0.05, C-index = 0.73), Basal layer NC (p < 0.05, C-index = 0.70) and PEL count (p < 0.05, C-index = 0.73) shown association of these features with a high risk of malignant transformation. Our work shows the application of deep learning for prognostication and progression free survival (PFS) prediction of OED for the first time and has a significant potential to aid patient management. Further evaluation and testing on multi-centric data is required for validation and translation to clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RMSB is funded by the Chancellor Scholarship from University of Warwick. HM is funded by a NIHR Doctoral Research Fellowship. AS, NA, SAK and NMR are funded by a Cancer Research UK Project Grant (ANTICIPATE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
WSIs were scanned after ethical approval (REC Reference- 18/WM/0335, NHS Health Research Authority West Midlands).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior authorship
Data Availability
All data produced in the present study are available upon reasonable request to the authors
